Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner.

  title={Detecting familial hypercholesterolaemia in the community: impact of a telephone call from a chemical pathologist to the requesting general practitioner.},
  author={Damon A. Bell and Amanda J. Hooper and Glenn Edwards and Lynda Southwell and Jing Pang and Frank M. van Bockxmeer and Gerald Francis Watts and John R. Burnett},
  volume={234 2},

Tables from this paper

Identifying undiagnosed or undertreated patients with familial hypercholesterolemia from the laboratory records of a tertiary medical center.

It was revealed that a significant number of FH patients were not taking statins despite having a very high LDL-C level, which may help to better understand and manage these high-risk patients.

Familial hypercholesterolaemia: challenges in primary care

The significance of FH is generally not well appreciated among GPs and patients in the Australian community, with the result that most affected individuals remain undiagnosed, while many who are detected are often inadequately treated.

Implementation of a biochemical, clinical, and genetic screening programme for familial hypercholesterolemia in 26 centres in Spain: The ARIAN study

Despite its limitations, systematic collaboration between clinical laboratories and lipid units allows for the identification of large numbers of patients with a phenotypic or genetic diagnosis of FH, which will reduce their vascular risk.

Progress in the care of familial hypercholesterolaemia: 2016

Children in childhood is the optimal period for detecting FH, since low‐density lipoprotein cholesterol (LDL‐c) concentrations better differentiate affected from unaffected individuals, and the community laboratory has an important role in identifying FH.



Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre

Significant potential exists to identify new cases of FH in primary care who could act as new index cases for a family screening programme, and to uncover the degree of case overlap with secondary care.

Familial hypercholesterolaemia in primary care: knowledge and practices among general practitioners in Western Australia.

Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand.

FH diagnostic services in New Zealand appear significantly underdeveloped thereby denying affected people the opportunity of early treatment to reduce the risk of premature cardiovascular events.

Opportunistic screening for familial hypercholesterolaemia via a community laboratory

The community laboratory is well placed to screen opportunistically for subjects with potential hypercholesterolaemia, and may be achieved using either the MED-PED criteria or a serum LDL-cholesterol cut-off point of ≥6.5 mmol/L, irrespective of age.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease

There is an urgent worldwide need for diagnostic screening together with early and aggressive treatment of this extremely high-risk condition, familial hypercholesterolaemia.

Familial hypercholesterolaemia: a model of care for Australasia.

Genetic analysis of familial hypercholesterolaemia in Western Australia.

Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies

Cascade testing of relatives of patients with DFH and PFH is cost-effective when using a combination of DNA testing for known family mutations and LDL-cholesterol levels in the remaining families, and is more cost- effective than current primary prevention screening strategies.

Screening for familial hypercholesterolaemia

Summary Familial hypercholesterolaemia (FH) is an autosomal dominant disorder characterised by increased plasma concentrations of low density lipoprotein (LDL) cholesterol leading to atherosclerosis

Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.

The prevalence of familial hypercholesterolemia appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication.